Exploration of Asthma & Allergy

Table 1. Clinical manifestations of multiple chemical sensitivity (MCS) [1, 6]

Organ system	Symptoms
Respiratory	Tachypnea
	Sense of suffocating
	Dyspnea
	Asthma
	Bronchospasm
	Cough
Otorhinolaryngological	Hyperosmia
	Burning eyes—stinging sensation
	Laryngeal burning sensation
Neurological	Cephalgia
	Migraine
	Asthenia
	Trembling
	Attention deficit
	Dizziness
	Confusion
	Loss of concentration capacity
	Sensorial: abnormal perception of odors
	Sensorial: visual disturbances
	Sensorial: hyperacusis
	Insomnia
Dermatological	Pruritus
	Eczema
	Rash
	Urticaria/angioedema
	Skin photosensitivity
	Dermographism
Rheumatological	Arthralgia
Rheumatological	Myalgia
Cardiovascular	Palpitations
	Arrhythmia
	Tachycardia
Gastroenterological	Nausea
	Abdominal pain
	Irritable colon
Endocrinological	Dysthyroidism
	Adrenal gland disorders
	Pituitary disorders
Psychological/psychiatric	Anxiety
	Panic attacks
	Depression
	Bipolar disorder

Return to article view

The bold symptoms represent the most frequent symptoms in MCS

Declarations

Acknowledgments

Acknowledgments for the figurines in Figure 1: The Figure was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license.

Author contributions

CEL: Conceptualization, Writing—original draft, Writing—review & editing, Validation. NM: Methodology, Writing—review & editing, Supervision, Validation. FdB: Conceptualization, Writing—original draft, Writing—review & editing, Validation, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Del Casale A, Ferracuti S, Mosca A, Pomes LM, Fiaschè F, Bonanni L, et al. Multiple Chemical Sensitivity Syndrome: A Principal Component Analysis of Symptoms. Int J Environ Res Public Health. 2020;17:6551. [DOI] [PubMed] [PMC]

Black DW, Temple S. Idiopathic environmental intolerance (multiple chemical sensitivity) [Internet]. UpToDate, Inc. and/or its affiliates; 2024 [cited 2024 Feb 7]. Available from: https://www.uptodate.com/contents/idiopathic-environmental-intolerance-multiple-chemical-sensitivity/print

Idiopathic environmental intolerances. J Allergy Clin Immunol. 1999;103:36–40. [DOI] [PubMed]

Cui X, Lu X, Hisada A, Fujiwara Y, Katoh T. The correlation between mental health and multiple chemical sensitivity: a survey study in Japanese workers. Environ Health Prev Med. 2015;20:123–9. [DOI] [PubMed] [PMC]

Rossi S, Pitidis A. Multiple Chemical Sensitivity: Review of the State of the Art in Epidemiology, Diagnosis, and Future Perspectives. J Occup Environ Med. 2018;60:138–46. [DOI] [PubMed] [PMC]

Damiani G, Alessandrini M, Caccamo D, Cormano A, Guzzi G, Mazzatenta A, et al. Italian Expert Consensus on Clinical and Therapeutic Management of Multiple Chemical Sensitivity (MCS). Int J Environ Res Public Health. 2021;18:11294. [DOI] [PubMed] [PMC]

Lu X, Hisada A, Anai A, Nakashita C, Masuda S, Fujiwara Y, et al. Study of the Correlation Between Multiple Chemical Sensitivity and Personality Using the Quick Environmental Exposure Sensitivity Inventory Questionnaire and the Temperament and Character Inventory. J Occup Environ Med. 2020;62:e348–54. [DOI] [PubMed] [PMC]

Hausteiner C, Bornschein S, Hansen J, Zilker T, Förstl H. Self-reported chemical sensitivity in Germany: a population-based survey. Int J Hyg Environ Health. 2005;208:271–8. [DOI] [PubMed]

Pigatto PD, Guzzi G. Prevalence and risk factors for multiple chemical sensitivity in Australia. Prev Med Rep. 2019;14:100856. [DOI] [PubMed] [PMC]

10.

Zucco GM, Doty RL. Multiple Chemical Sensitivity. Brain Sci. 2022;12:46. [DOI] [PubMed] [PMC]

11.

Cullen MR. The worker with multiple chemical sensitivities: an overview. Occup Med. 1987;2:655–61. [PubMed]

12.

McKeown-Eyssen G, Baines C, Cole DE, Riley N, Tyndale RF, Marshall L, et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol. 2004;33:971–8. [DOI] [PubMed]

13.

Lacour M, Zunder T, Schmidtke K, Vaith P, Scheidt C. Multiple chemical sensitivity syndrome (MCS) – suggestions for an extension of the U.S. MCS-case definition. Int J Hyg Environ Health. 2005;208:141–51. [DOI] [PubMed]

14.

Palmer RF, Jaén CR, Perales RB, Rincon R, Forster JN, Miller CS. Three questions for identifying chemically intolerant individuals in clinical and epidemiological populations: The Brief Environmental Exposure and Sensitivity Inventory (BREESI). PLoS One. 2020;15:e0238296. [DOI] [PubMed] [PMC]

15.

Palmer RF, Walker T, Kattari D, Rincon R, Perales RB, Jaén CR, et al. Validation of a Brief Screening Instrument for Chemical Intolerance in a Large U.S. National Sample. Int J Environ Res Public Health. 2021;18:8714. [DOI] [PubMed] [PMC]

16.

Miller CS, Prihoda TJ. The Environmental Exposure and Sensitivity Inventory (EESI): a standardized approach for measuring chemical intolerances for research and clinical applications. Toxicol Ind Health. 1999;15:370–85. [DOI] [PubMed]

17.

Barnig C, Kopferschmitt MC, de Blay F. Multiple chemical sensitivities: Pathophysiology and clinical aspects. Rev Fr Allergol Immunol Clin. 2007;47:250–2. French. [DOI]

18.

Barnig C, de Blay F. Pathophysiology of multiple chemical sensitivity. Rev Mal Respir. 2013;30:446–50. French. [DOI] [PubMed]

19.

Moulton PV, Yang W. Air pollution, oxidative stress, and Alzheimer’s disease. J Environ Public Health. 2012;2012:472751. [DOI] [PubMed] [PMC]

20.

Hodges RE, Minich DM. Modulation of Metabolic Detoxification Pathways Using Foods and Food-Derived Components: A Scientific Review with Clinical Application. J Nutr Metab. 2015;2015:760689. [DOI] [PubMed] [PMC]

21.

Szyf M. The dynamic epigenome and its implications in toxicology. Toxicol Sci. 2007;100:7–23. [DOI] [PubMed]

22.

Thier R, Brüning T, Roos PH, Rihs HP, Golka K, Ko Y, et al. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int J Hyg Environ Health. 2003;206:149–71. [DOI] [PubMed]

23.

De Luca C, Scordo MG, Cesareo E, Pastore S, Mariani S, Maiani G, et al. Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes. Toxicol Appl Pharmacol. 2010;248:285–92. [DOI] [PubMed]

24.

Cui X, Lu X, Hiura M, Oda M, Miyazaki W, Katoh T. Evaluation of genetic polymorphisms in patients with multiple chemical sensitivity. PLoS One. 2013;8:e73708. [DOI] [PubMed] [PMC]

25.

De Luca C, Gugliandolo A, Calabrò C, Currò M, Ientile R, Raskovic D, et al. Role of polymorphisms of inducible nitric oxide synthase and endothelial nitric oxide synthase in idiopathic environmental intolerances. Mediators Inflamm. 2015;2015:245308. [DOI] [PubMed] [PMC]

26.

Pall ML. Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: central role of N-methyl-D-aspartate receptors in the sensitivity mechanism. Environ Health Perspect. 2003;111:1461–4. [DOI] [PubMed] [PMC]

27.

Pall ML. Multiple chemical sensitivity is a response to chemicals acting as toxicants via excessive NMDA activity. J Psychosom Res. 2010;69:327–8. [DOI] [PubMed]

28.

Molot J, Sears M, Marshall LM, Bray RI. Neurological susceptibility to environmental exposures: pathophysiological mechanisms in neurodegeneration and multiple chemical sensitivity. Rev Environ Health. 2022;37:509–30. [DOI] [PubMed]

29.

Steinritz D, Stenger B, Dietrich A, Gudermann T, Popp T. TRPs in Tox: Involvement of Transient Receptor Potential-Channels in Chemical-Induced Organ Toxicity—A Structured Review. Cells. 2018;7:98. [DOI] [PubMed] [PMC]

30.

Li N, Sioutas C, Cho A, Schmitz D, Misra C, Sempf J, et al. Ultrafine particulate pollutants induce oxidative stress and mitochondrial damage. Environ Health Perspect. 2003;111:455–60. [DOI] [PubMed] [PMC]

31.

Hofman J, Staelens J, Cordell R, Stroobants C, Zikova N, Hama SML, et al. Ultrafine particles in four European urban environments: Results from a new continuous long-term monitoring network. Atmos Environ. 2016;136:68–81. [DOI]

32.

Nazaroff WW, Weschler CJ. Cleaning products and air fresheners: exposure to primary and secondary air pollutants. Atmos Environ. 2004;38:2841–65. [DOI]

33.

Ebersviller S, Lichtveld K, Sexton KG, Zavala J, Lin YH, Jaspers I, et al. Gaseous VOCs rapidly modify particulate matter and its biological effects – Part 1: Simple VOCs and model PM. Atmos Chem Phys Discuss. 2012;12:5065–105. [DOI] [PubMed] [PMC]

34.

Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20:1126–67. [DOI] [PubMed] [PMC]

35.

Burch WM. Passage of inhaled particles into the blood circulation in humans. Circulation. 2002;106:e141–2. [DOI] [PubMed]

36.

Traboulsi H, Guerrina N, Iu M, Maysinger D, Ariya P, Baglole CJ. Inhaled Pollutants: The Molecular Scene behind Respiratory and Systemic Diseases Associated with Ultrafine Particulate Matter. Int J Mol Sci. 2017;18:243. [DOI] [PubMed] [PMC]

37.

Babadjouni R, Patel A, Liu Q, Shkirkova K, Lamorie-Foote K, Connor M, et al. Nanoparticulate matter exposure results in neuroinflammatory changes in the corpus callosum. PLoS One. 2018;13:e0206934. [DOI] [PubMed] [PMC]

38.

Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev. 2006;58:140–61. [DOI] [PubMed]

39.

Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60:196–209. [DOI] [PubMed] [PMC]

40.

Block ML, Calderón-Garcidueñas L. Air pollution: mechanisms of neuroinflammation and CNS disease. Trends Neurosci. 2009;32:506–16. [DOI] [PubMed] [PMC]

41.

Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36:437–49. [DOI] [PubMed]

42.

Daneman R. The blood-brain barrier in health and disease. Ann Neurol. 2012;72:648–72. [DOI] [PubMed]

43.

Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:65–75. [DOI] [PubMed]

44.

Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, et al. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol. 2004;16:437–45. [DOI] [PubMed]

45.

Garcia GJ, Schroeter JD, Kimbell JS. Olfactory deposition of inhaled nanoparticles in humans. Inhal Toxicol. 2015;27:394–403. [DOI] [PubMed] [PMC]

46.

Vennekens R, Menigoz A, Nilius B. TRPs in the Brain. In: Nilius B, Amara SG, Gudermann T, Jahn R, Lill R, Offermanns S, et al., editors. Reviews of Physiology, Biochemistry and Pharmacology, Vol. 163. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. pp. 27–64. [DOI] [PubMed]

47.

Bessac BF, Jordt SE. Breathtaking TRP channels: TRPA1 and TRPV1 in airway chemosensation and reflex control. Physiology (Bethesda). 2008;23:360–70. [DOI] [PubMed] [PMC]

48.

Lanosa MJ, Willis DN, Jordt S, Morris JB. Role of metabolic activation and the TRPA1 receptor in the sensory irritation response to styrene and naphthalene. Toxicol Sci. 2010;115:589–95. [DOI] [PubMed] [PMC]

49.

Brooks SM, Weiss MA, Bernstein IL. Reactive airways dysfunction syndrome (RADS): Persistent asthma syndrome after high level irritant exposures. Chest. 1985;88:376–84. [DOI] [PubMed]

50.

Schumacher MA. Transient receptor potential channels in pain and inflammation: therapeutic opportunities. Pain Pract. 2010;10:185–200. [DOI] [PubMed] [PMC]

51.

Upregulation [Internet]. [cited 2023 Aug 20]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/upregulation

52.

Steinemann A. National Prevalence and Effects of Multiple Chemical Sensitivities. J Occup Environ Med. 2018;60:e152–6. [DOI] [PubMed] [PMC]

53.

Fleming KC, Volcheck MM. Central sensitization syndrome and the initial evaluation of a patient with fibromyalgia: a review. Rambam Maimonides Med J. 2015;6:e0020. [DOI] [PubMed] [PMC]

54.

Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895–926. [DOI] [PubMed] [PMC]

55.

Bell IR, Szarek MJ, Dicenso DR, Baldwin CM, Schwartz GE, Bootzin RR. Patterns of waking EEG spectral power in chemically intolerant individuals during repeated chemical exposures. Int J Neurosci. 1999;97:41–59. [DOI] [PubMed]

56.

Hillert L, Musabasic V, Berglund H, Ciumas C, Savic I. Odor processing in multiple chemical sensitivity. Hum Brain Mapp. 2007;28:172–82. [DOI] [PubMed] [PMC]

57.

Orriols R, Costa R, Cuberas G, Jacas C, Castell J, Sunyer J. Brain dysfunction in multiple chemical sensitivity. J Neurol Sci. 2009;287:72–8. [DOI] [PubMed]

58.

Miki T, Inoue Y, Miyajima E, Kudo Y, Tsunoda M, Kan S, et al. Enhanced brain images in the limbic system by functional magnetic resonance imaging (fMRI) during chemical exposures to patients with multiple chemical sensitivities. Kitasato Med J. 2010;40:27–34.

59.

Bornschein S, Hausteiner C, Drzezga A, Theml T, Heldmann B, Grimmer T, et al. Neuropsychological and positron emission tomography correlates in idiopathic environmental intolerances. Scand J Work Environ Health. 2007;33:447–53. [DOI] [PubMed]

60.

Vojdani A, Ghoneum M, Brautbar N. Immune alteration associated with exposure to toxic chemicals. Toxicol Ind Health. 1992;8:239–54. [DOI] [PubMed]

61.

Dantoft TM, Elberling J, Brix S, Szecsi PB, Vesterhauge S, Skovbjerg S. An elevated pro-inflammatory cytokine profile in multiple chemical sensitivity. Psychoneuroendocrinology. 2014;40:140–50. [DOI] [PubMed]

62.

Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 1998;62:583–606. [DOI] [PubMed]

63.

Simon GE, Daniell W, Stockbridge H, Claypoole K, Rosenstock L. Immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity. A controlled study. Ann Intern Med. 1993;119:97–103. [DOI] [PubMed]

64.

Binkley KE, Kutcher S. Panic response to sodium lactate infusion in patients with multiple chemical sensitivity syndrome. J Allergy Clin Immunol. 1997;99:570–4. [DOI] [PubMed]

65.

Otto T, Giardino ND. Pavlovian conditioning of emotional responses to olfactory and contextual stimuli: a potential model for the development and expression of chemical intolerance. Ann N Y Acad Sci. 2001;933:291–309. [DOI] [PubMed]

66.

Fiedler N, Kipen HM, DeLuca J, Kelly-McNeil K, Natelson B. A controlled comparison of multiple chemical sensitivities and chronic fatigue syndrome. Psychosom Med. 1996;58:38–49. [DOI] [PubMed]

67.

Staudenmayer H, Selner ME, Selner JC. Adult sequelae of childhood abuse presenting as environmental illness. Ann Allergy. 1993;71:538–46. [PubMed]

68.

Fernandez M, Bell IR, Schwartz GE. EEG sensitization during chemical exposure in women with and without chemical sensitivity of unknown etiology. Toxicol Ind Health. 1999;15:305–12. [DOI] [PubMed]

69.

Skovbjerg S, Christensen KB, Ebstrup JF, Linneberg A, Zachariae R, Elberling J. Negative affect is associated with development and persistence of chemical intolerance: a prospective population-based study. J Psychosom Res. 2015;78:509–14. [DOI] [PubMed]

70.

Bailer J, Witthöft M, Rist F. Psychological predictors of short- and medium term outcome in individuals with idiopathic environmental intolerance (IEI) and individuals with somatoform disorders. J Toxicol Environ Health A. 2008;71:766–75. [DOI] [PubMed]

71.

Bornschein S, Förstl H, Zilker T. Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives. J Intern Med. 2001;250:309–21. [DOI] [PubMed]

72.

Caress SM, Steinemann AC. Prevalence of multiple chemical sensitivities: a population-based study in the southeastern United States. Am J Public Health. 2004;94:746–7. [DOI] [PubMed] [PMC]

73.

Leznoff A. Provocative challenges in patients with multiple chemical sensitivity. J Allergy Clin Immunol. 1997;99:438–42. [DOI] [PubMed]

74.

Millqvist E, Löwhagen O. Placebo-controlled challenges with perfume in patients with asthma-like symptoms. Allergy. 1996;51:434–9. [DOI] [PubMed]

75.

Bornschein S, Hausteiner C, Römmelt H, Nowak D, Förstl H, Zilker T. Double-blind placebo-controlled provocation study in patients with subjective Multiple Chemical Sensitivity (MCS) and matched control subjects. Clin Toxicol (Phila). 2008;46:443–9. [DOI] [PubMed]

76.

Azuma K, Uchiyama I, Tanigawa M, Bamba I, Azuma M, Takano H, et al. Association of Odor Thresholds and Responses in Cerebral Blood Flow of the Prefrontal Area during Olfactory Stimulation in Patients with Multiple Chemical Sensitivity. PLoS One. 2016;11:e0168006. [DOI] [PubMed] [PMC]

77.

Das-Munshi J, Rubin GJ, Wessely S. Multiple chemical sensitivities: A systematic review of provocation studies. J Allergy Clin Immunol. 2006;118:1257–64. [DOI] [PubMed]

78.

Ross GH. Treatment options in multiple chemical sensitivity. Toxicol Ind Health. 1992;8:87–94. [DOI] [PubMed]

79.

Molot J, Sears M, Anisman H. Multiple chemical sensitivity: It’s time to catch up to the science. Neurosci Biobehav Rev. 2023;151:105227. [DOI] [PubMed]

80.

Policy on Environmental Sensitivities [Internet]. Ottawa: Canadian Human Rights Commission; [cited 2024 Feb 8]. Available from: https://www.chrc-ccdp.gc.ca/en/resources/publications/policy-environmental-sensitivities

81.

Hauge CR, Rasmussen A, Piet J, Bonde JP, Jensen C, Sumbundu A, et al. Mindfulness-based cognitive therapy (MBCT) for multiple chemical sensitivity (MCS): Results from a randomized controlled trial with 1 year follow-up. J Psychosom Res. 2015;79:628–34. [DOI] [PubMed]

82.

Cozzolino M, Celia G, Rossi KL, Rossi EL. Hypnosis as Sole Anesthesia for Dental Removal in a Patient with Multiple Chemical Sensitivity. Int J Clin Exp Hypn. 2020;68:371–83. [DOI] [PubMed]